| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.0084 | 0.8 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | 0.0072 | 0.9 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.47 | 2e-40 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.43 | 2e-34 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.24 | 2e-13 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.22 | 1e-09 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
| mRNA | decitabine:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 2e-05 |